Cancer drug safety under watch: Year-Long side effect tracking begins
NCT ID NCT05021562
Summary
This study aims to monitor side effects in ovarian cancer patients taking the maintenance drug niraparib (Zedula). It will follow 354 participants for one year after they start treatment, tracking specific safety concerns like blood cell problems and high blood pressure. The study observes patients receiving standard care rather than testing a new treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.